Global Gene Therapy Market By Vector Type (Viral Vector(Retroviral, Adeno-associated) and Non – Viral(Oligonucleotides) Vector), By Gene Type (Antigen, Receptor, Growth Factors, Cytokine), By Delivery Method (Ex-Vivo & In Vivo Therapy), By Disease Indication (Ophthalmology, Neurology, Hematology) and Duchenne Muscular Dystrophy), By Distribution Channel (Hospitals, Clinics), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Report Overview

The global gene therapy market size is expected to be worth around USD 49.3 Bn by 2032 from USD 5.6 Bn in 2022, growing at a CAGR of 25% during the forecast period from 2022 to 2032.

Gene therapy is a procedure that modifies a person’s genes to cure a disease. It is a medical approach that prevents or treats disease by correcting underline problems. This technique allows doctors to treat the disorder by changing a person’s genetic makeup using drugs or surgery. Gene therapy can work by several mechanisms.

Gene therapies are used to treat a small number of diseases. Many gene therapies undergo research to make  that they will be safe and effective. Gene is a functional heredity of life that carries instructions for a particular function. This therapy includes exchanging defective genes in the patient’s body for healthy ones to prevent disease proliferation.

There are two types of gene therapy based on the target gene: germline gene therapy and somatic gene therapy. It can treat several diseases, such as Alzheimer’s, Cystic fibrosis, brain tumors, AIDS, cancer, and Hemophilia.

Key Takeaways

• In 2022, the viral vector category contributed significantly to the total revenue, accounting for an impressive 85% share.
• When considering gene types, the antigens category emerged as the leader in terms of market revenue share for the year 2022.
• Among the various delivery methods, the in-vivo approach stood out as the top revenue generator throughout the forecast period spanning from 2023 to 2032.
• Looking at disease indications, the oncology sector established its dominance in the market, exhibiting the highest Compound Annual Growth Rate (CAGR) during the forecast period.
• The distribution channel that made the most impact was the hospital segment, with a remarkable 8.8% CAGR from 2023 to 2032.
• In 2022, North America secured its position as the market leader, boasting the highest revenue share at 65%.

Type Analysis

The gene therapy market is segmented by type into viral (retroviral & adeno-associated) and non-viral vectors (oligonucleotides). The viral vector segment is anticipated to hold the largest revenue share of over 85% during the forecast period. Owing to the development of physiological methods for gene therapies during clinical and preclinical studies to treat various diseases, the viral vector segment is anticipated to grow fast during the forecast period.

Adenovirus lentiviruses, retrovirus, adeno-associated viruses, poxvirus, simplex viruses, herpes, vaccinia viruses, and other viruses are subdivided into the viral vector segment. Further divisions of non-viral vectors include naked/plasmid vectors, gene guns, electroporation, lipofection, and others.

On the other hand, the non-viral vector section is anticipated to be the most adaptable section during the forecast period. This is because of the extensive availability of non-viral vector gene treatments based on oligonucleotides. The prevalence of cancer and other target diseases is increasing, reimbursement policies are available, and funding for gene therapy research is expanding. These are the main drivers predicting market expansion in the following years.

Gene Type Analysis

The market can be divided based on gene type into growth factors, antigens, receptors, cytokines, and others. The antigen section has held the largest market share during the forecast period. Increasing the prevalence of autoimmune disease cancer and R & D in antigen-based therapies, are key factors predicted to drive the market growth during the upcoming period.

Delivery Methods Analysis

Based on Delivery methods the market is categorized into in-vivo and ex-vivo. The in-vivo method segment held the largest share of the market during the forecast period. An increase in the selection of in-vivo therapies globally is anticipated to drive the market’s growth in the future.

Disease Indication Analysis

Based on application, the market is classified into Ophthalmology, Neurology, Hematology, Oncology, Infectious Disease, and Cardiology. The Oncology section dominated the global gene therapy market share during the forecast period in revenue and is anticipated to sustain its dominance.

The oncological disorder is expected to grow the fastest CAGR during the forecast period due to the approval of gene therapies for cancer therapy. Instead of the Neurology section, estimate the most considerate area during the forecast period.

Gene therapy market shares due to the high cost of the drug combined with a more extensive selection of the treatment type among neurology patients suffering from spinal muscular atrophy.

Distribution Channel Analysis

Based on distribution channel the market is divided into hospitals, clinics and others The Hospitals segment is anticipated to have the highest share in the market throughout the forecast period, and the dominance is due to the accessibility and availability of treatment methods in such facilities. The section is expected to maintain its dominance in the market during the forecast period. The clinics

segment is also expected to experience growth due to increase number of clinics offering advanced therapies for neurological and caner condition.

Key Market Segments

Based on Vector Type

• Viral Vectors (Retroviral, Adeno-Associated)
• Non-Viral Vectors (Oligonucleotides)

Based on Gene Type

• Antigen
• Receptor
• Growth Factors
• Cytokine
• Others

Based on the Delivery Method

• In-Vivo
• Ex-Vivo

Based on Disease Indication

• Ophthalmology
• Neurology
• Hematology
• Oncology
• Infectious Disease
• Cardiology

Based On the Distribution Channel

• Hospitals
• Pharmaceutical & Biochemical Companies
• Research Centers
• Academic Institutions

Drivers

Rising Prevalence of Neurological and Oncology Disorder to Booster Market Growth

One of the leading drivers for the global gene therapy market is rare genetic disorders among the population. According to National Organization for Rare Diseases, the predicted incidence of spinal muscular atrophy is 1 in 10,000 live births in the US per year. Technological advancement in the field has helped the treatment of such diseases that have that were untreatable. The increasing research studies and inventions are anticipated to impact the market significantly.

The US Food and Drug Administration predicts receiving more than 200 applications of the therapy. Corresponding to the Alliance of Regenerative Medicine, there are around 259 applicants in Phase 1 Clinical trials worldwide. The highest percentage of research is launched in oncology applications. To increasing activities and research studies in the market are the major factors driving the growth of the market. The availability of many gene therapy products that can be used to treat cancer and a large patient population base anticipated to drive the growth of the market in upcoming years.

Restraints

Exorbitant Cost of Treatment Method is Estimated to Restrain Market Growth

The treatment technique is costly, and chronic disorders such as cancer are increasing. The method is displayed as a single dose of treatment authority that reverses the patient’s body dysfunction. The high charge of this expensive therapy has also encouraged unwillingness to compensate for the treatment method by some insurance companies. These influences could largely influence the growth of the gene therapy market during the forthcoming years.

Opportunity

Gene Therapy Encouraging Revenue Generation of Companies

Gene therapy is encouraging to generate revenue for pharmaceutical and biochemical companies. Presently maximum key players are focusing on new gene products to maximize the gene therapy market opportunities. Some of these products are in the preclinical stage; others are in the clinical phase and anticipated to secure approval in the upcoming years.

In addition, the gene therapy industry focuses on diseases such as hemophilia, fabric disease, and multiple myeloma. Therefore, the patient pool for gene therapies is anticipated to create opportunities in the coming years.

Trends

Shift Towards Advanced Treatment Options to cure Chronic Diseases is a Prominent Trend

Advanced countries are developing advanced treatment options for chronic diseases. Therefore, it is a leading shift in adopting this treatment for conventional treatment options like chemotherapy that have severe side effects and long-term implications. There is also a shift towards adopting viral vectors that provide high immunogenicity and lower toxicity for such therapies.

Regional Analysis

North America Market Dominate with Highest Revenue During the Forecast Period

Based on the region, the global market can be sectioned into North America, Europe, APAC, South America, Middle East & Africa. Among these, the North America region is accounted for the major share of revenue at 65% during the forecast period. The main factors driving the market growth are increasing numbers of investments by private and government, advancements in research and development related to gene therapy, and the growing frequency of target diseases. North America is the largest regional market for gene therapy A.

Presence of key market players in the region attribute to a large share of North America in the global market Similarly, Europe is highly receptive to advanced treatment options for incurable diseases. Higher search funding in such a field would drive market growth. Instead, Asia – Pacific holds significantly less market share revenue. The principal reason for these less selection phase treatments of this type because of its high cost. Developing Countries such as India demonstrate guidelines for releasing and marketing products in the country.

Key Regions

• North America
  • The US
  • Canada
  • Mexico

• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe

• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe

• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC

• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America

• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The global market is highly extending and consists of major market prominent players like Novartis AG, Amgen Inc., Jazz Pharmaceuticals, Orchard Therapeutics, Sunway Biotech, Merck & CO, Inc. Bluebird Bio, Inc. Biogen, Gilead Science, BioMarin Pharmaceutical Inc., and Applied Genetic Corporation. They have various conscious associations such as acquisitions and collaborations, including launching progressive products to secure their position in the global market.

Market players positioning facilities evaluate and provide a clear understanding of the present position of the market players. A few drugs are approved worldwide for treating genetic disorders, and this has leading dominance for such players in the market. Moreover, several candidates from other pharmaceutical companies are in preclinical and clinical stages that are until to be approved by regulatory authorities.

Listed below are some of the most prominent Gene Therapy Market industry players.

Market Key Players

• Novartis AG
• Biogen
• Gilead Science, Inc.
• Spark Therapeutics, Inc.
• Amgen, Inc.
• Jazz Pharmaceuticals, Inc.
• GlaxoSmithKline plc.
• Spartea Therapeutics
• Sibiono Gene Tech Co, Ltd.
• Orchard Therapeutics
• Bluebird Bio, Inc.
• Sunway Biotech CO, Ltd.
• Applied Genetic Corporation
• Astellas Therapeutics
• Merck & CO, Inc.
• REGENXIBO Inc.
• Sangamo Therapeutics, Inc.
• Cipla Inc.
• Intellia Therapeutics, Inc.
• BioMarin Pharmaceuticals Inc.
• Other Key Players

Recent Development

June 2021  Biogen Inc. announced positive results from their phase 3-star study of their timrepigene empacrvovec, an investigational gene therapy treatment of choroideremia.

February 2021  Spark Therapeutics announced that the first study participant had been dosed in the US region as a part of an international gene therapy clinical trial related to Pompe disease.

Report Scope